### 11th PDWP, IDWP, IEWP and Pediatric Nurse Group Meeting

**Palazzo della Gran Guardia**

**Verona, 7–9 June 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.00</td>
<td>Registration and Welcome Lunch</td>
</tr>
<tr>
<td>14.00</td>
<td>Welcome greetings and introduction of the 11th Congress of PDWP</td>
</tr>
<tr>
<td></td>
<td>(in collaboration with IEWP, IDWP, and Pediatric NG)</td>
</tr>
</tbody>
</table>

**Authorities:**

- City Mayor or his delegate: Daphna Hutt
- Hospital Director: Arjan Lankester
- President AIEO (Parent Association of Verona): Jan Styczynski
- Local Organizers: Peter Bader
- Simone Cesaro
- Alberto Castagna

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30</td>
<td>I Session: (IEWP session) New trends in immunodeficiency and inborn</td>
</tr>
<tr>
<td></td>
<td>errors</td>
</tr>
<tr>
<td>14.45</td>
<td>II Session: Cutting Edge in haplo-identical transplantation for patient</td>
</tr>
<tr>
<td></td>
<td>with acute leukemia</td>
</tr>
<tr>
<td>20.30</td>
<td>Social Dinner</td>
</tr>
<tr>
<td>09.00</td>
<td>III session: State of the Art and perspectives in Congenital Bone</td>
</tr>
<tr>
<td></td>
<td>Marrow Failure</td>
</tr>
<tr>
<td>10.45</td>
<td>IV Session: (IDWP session) Progresses in treating infectious</td>
</tr>
<tr>
<td></td>
<td>complications</td>
</tr>
</tbody>
</table>

**NURSES**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.00</td>
<td>Registration and Welcome Lunch</td>
</tr>
</tbody>
</table>

**Joint Session**

** Authorities:**

- City Mayor or his delegate
- Hospital Director
- President AIEO
- Local Organizers
- Simone Cesaro
- Alberto Castagna

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30</td>
<td>Introduction to nurse activities:</td>
</tr>
<tr>
<td></td>
<td>Welcome to the nurses sessions</td>
</tr>
<tr>
<td></td>
<td>EBMT NS activities / EBMT NS Board 10'</td>
</tr>
<tr>
<td></td>
<td>Pediatric committee activities 10'</td>
</tr>
<tr>
<td></td>
<td>Interactive introduction 10'</td>
</tr>
<tr>
<td></td>
<td>Italian group presents their activities GITMD - AIEOP 10'</td>
</tr>
<tr>
<td></td>
<td>Multi-cultural Care:</td>
</tr>
<tr>
<td></td>
<td>Nurse global perspective 20'</td>
</tr>
<tr>
<td></td>
<td>Psychologist perspective 20'</td>
</tr>
<tr>
<td>16.45</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>16.45</td>
<td>Taking care of the paediatric SCT family</td>
</tr>
<tr>
<td>17.45</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>20.30</td>
<td>Social Dinner</td>
</tr>
</tbody>
</table>

**Joint meeting**

**State of the Art**

- Role of mitochondrial defects in Fanconi anemia: potential correlations between genotype and phenotype: A. Savoia
- Gene therapy for Blackfan-Diamond: Marcin Wlodarsky

**Clinical Case 1**

- Chair: JH. Dalle, E. Lanino

**Clinical Case 2**

**Clinical Case 3**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.45</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11.15</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11.45</td>
<td>IV Session: (IDWP session) Progresses in treating infectious</td>
</tr>
<tr>
<td></td>
<td>complications</td>
</tr>
<tr>
<td></td>
<td>New treatment approach for Ad-enoirus</td>
</tr>
<tr>
<td></td>
<td>Progress in prophylaxis and treatment of mold infection</td>
</tr>
<tr>
<td></td>
<td>Prophylaxis and treatment of G neg infection</td>
</tr>
</tbody>
</table>

**Clinical Case 1**

- Chair: Jan Styczynski

**Clinical Case 2**

**Clinical Case 3**

### FRIDAY 8th June 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>Joint session</td>
</tr>
<tr>
<td></td>
<td>State of the Art</td>
</tr>
<tr>
<td></td>
<td>C. Dufour</td>
</tr>
</tbody>
</table>

**Clinical Case 1**

- Chair: JH. Dalle, E. Lanino

**Clinical Case 2**

**Clinical Case 3**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.45</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11.15</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11.45</td>
<td>Nurses research in paediatric HSCT patients</td>
</tr>
<tr>
<td>13.00</td>
<td>Research committee: How to propose a study?</td>
</tr>
<tr>
<td></td>
<td>M. Canesi</td>
</tr>
<tr>
<td></td>
<td>AIEOP study. How to identify the critical oncological pediatric patient:</td>
</tr>
<tr>
<td></td>
<td>0-PEW/TBDD</td>
</tr>
<tr>
<td></td>
<td>EBMT NS Paediatric Grant 2017:</td>
</tr>
<tr>
<td></td>
<td>Results of Turkish Pediatric Hematopoietic Stem Cell Nursing Profile</td>
</tr>
<tr>
<td></td>
<td>Study 2 Medine Çalışkan Yılmaz</td>
</tr>
</tbody>
</table>

**Chair**

- Hilda Mekelenkamp
13.00  14.00 Lunch


Monoclonal antibodies: cure without SCT
- JH Dalle

New approaches in CART-cell therapy
- P. Amrolia

CART-cell against CD19 leukemia
- Joshua Buchner

CIK cells for preemptive immunotherapy
- Ewa Rettinger

Clinical Case 1
- Chair: R. Meisel

Clinical Case 2

Clinical Case 3

14.00  14.45 Non-malignant disease

- Daphna Hutt

Non-malignant diseases 25+5
- TBD

Topic & Speaker: to be defined 25+5
- Hilda Mekelenkamp

Shared decision making in SCT 25+5
- Open discussion

15.45  16.15 Coffee Break

16.15  18.00 VI Session: Frontiers of Precision medicine

Early and late complications

- The treatment of mucositis: what is new? Low Level Laser Therapy 20+5
  - F. Verzagnassi

- VOD – EBMT Pediatric guidelines 20+5
  - Helen Webster

- GVHD treatment 20+5
  - M. Beltrame, N. Colon

- Chair

- Marta Canesi

Impact of KIR typing in patients with HLA identical donors
- F. Barbior

Genomic alterations in ALL re-lapses post allogeneic HSCT
- R. Mesiel

New insights in the importance of Pharmacogenomics in the dose adjustment of the condition
- Marc Ansari

Clinical Case 1

Clinical Case 2

Clinical Case 3

Chair

18.00  19.00 Free evening
Poster visit and poster round
- Marco Rabusin

17.30  19.00 Visit to the SCU
Free evening

09.00  10.20 VII Session: New developments in the diagnosis and treatment of immediate complications (I)

Optimizing serotherapy in HSCT
- A. Lankester

A novel method to generate MSC and it’s clinical options
- P. Bader

Clinical Case 1

Clinical Case 2

Clinical Case 3

Chair

Mauro Krampera

10.20  10.40 Coffee Break

10.40  12.05 VIII Session: New developments in the diagnosis and treatment of immediate complications (II)

Endothelial associated diseases
- Selim Corbacioglu

Acute GVHD, incidence, treat-ment and outcome
- A. Bertaina

ECP for aGVHD
- Anna Lawitska

Clinical Case 1

Clinical Case 2

Clinical Case 3

Chair

Christine Peters

12.05  12.30 Closure of the meeting (Bader, Lankester, Styczynski, Hutt, Cesaro)

12.30  13.00 Goodby light lunch

14.00  14.45 Non-malignant disease

- Daphna Hutt

Non-malignant diseases 25+5
- TBD

Topic & Speaker: to be defined 25+5
- Hilda Mekelenkamp

Shared decision making in SCT 25+5
- Open discussion

15.45  16.15 Coffee Break

16.15  18.00 VI Session: Frontiers of Precision medicine

Early and late complications

- The treatment of mucositis: what is new? Low Level Laser Therapy 20+5
  - F. Verzagnassi

- VOD – EBMT Pediatric guidelines 20+5
  - Helen Webster

- GVHD treatment 20+5
  - M. Beltrame, N. Colon

- Chair

- Marta Canesi

Impact of KIR typing in patients with HLA identical donors
- F. Barbior

Genomic alterations in ALL re-lapses post allogeneic HSCT
- R. Mesiel

New insights in the importance of Pharmacogenomics in the dose adjustment of the condition
- Marc Ansari

Clinical Case 1

Clinical Case 2

Clinical Case 3

Chair

18.00  19.00 Free evening
Poster visit and poster round
- Marco Rabusin

17.30  19.00 Visit to the SCU
Free evening

09.00  10.20 VII Session: New developments in the diagnosis and treatment of immediate complications (I)

Optimizing serotherapy in HSCT
- A. Lankester

A novel method to generate MSC and it’s clinical options
- P. Bader

Clinical Case 1

Clinical Case 2

Clinical Case 3

Chair

Mauro Krampera

10.20  10.40 Coffee Break

10.40  12.05 VIII Session: New developments in the diagnosis and treatment of immediate complications (II)

Endothelial associated diseases
- Selim Corbacioglu

Acute GVHD, incidence, treat-ment and outcome
- A. Bertaina

ECP for aGVHD
- Anna Lawitska

Clinical Case 1

Clinical Case 2

Clinical Case 3

Chair

Christine Peters

12.05  12.30 Closure of the meeting (Bader, Lankester, Styczynski, Hutt, Cesaro)

12.30  13.00 Goodby light lunch

SCIENTIFIC COMMITTEE:
3 PDWP board: Selim Corbacioglu, Marc Ansari, Roland Meisel, Peter Bader
3 Local or Italian SCT working group: Simone Cesaro, Alice Bertaina, Adriana Balduzzi
2 IDWP: Jan Styczynski, Malgorzata Mikulska
2 IEWP: Arjan Lankester, Michael Albert
3 Pediatric nurses committee: Dafne Hutt, Teija Schroder, Hilda Mekelenkamp + 1 local organiser: Alberto Castagna

REGISTRATION FEES:
* Physicians 200€ (150€ for the early bird).
* Nurses, Students, Data Managers, Statisticians 50€
Early Bird fees available until 10th April 2018

IMPORTANT: Registration will be open during the week of the 5th of MARCH at the NEW EBMT Website. Please stay tuned! www.ebmt.org